MA38161A1 - Anticorps anti-bmp-6 - Google Patents

Anticorps anti-bmp-6

Info

Publication number
MA38161A1
MA38161A1 MA38161A MA38161A MA38161A1 MA 38161 A1 MA38161 A1 MA 38161A1 MA 38161 A MA38161 A MA 38161A MA 38161 A MA38161 A MA 38161A MA 38161 A1 MA38161 A1 MA 38161A1
Authority
MA
Morocco
Prior art keywords
bmp
antibody
antigen
antibodies
binding fragments
Prior art date
Application number
MA38161A
Other languages
English (en)
Inventor
Stephanie Marie Eaton Truhlar
Neungseon Seo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49918813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38161(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA38161A1 publication Critical patent/MA38161A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne des anticorps, ou des fragments de ceux-ci se liant à l'antigène, qui se lient à bmp-6 humaine, des compositions comprenant lesdits anticorps, ou les fragments de ceux-ci se liant à l'antigène, et des procédés les utilisant pour le traitement de l'anémie d'une maladie chronique.
MA38161A 2012-12-17 2013-12-05 Anticorps anti-bmp-6 MA38161A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737859P 2012-12-17 2012-12-17
PCT/US2013/073239 WO2014099391A1 (fr) 2012-12-17 2013-12-05 Anticorps anti-bmp-6

Publications (1)

Publication Number Publication Date
MA38161A1 true MA38161A1 (fr) 2017-12-29

Family

ID=49918813

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38161A MA38161A1 (fr) 2012-12-17 2013-12-05 Anticorps anti-bmp-6

Country Status (33)

Country Link
US (2) US8795665B2 (fr)
EP (1) EP2931748B1 (fr)
JP (1) JP6033459B2 (fr)
KR (1) KR20150083918A (fr)
CN (1) CN104870473B (fr)
AP (1) AP2015008600A0 (fr)
AR (1) AR093620A1 (fr)
AU (1) AU2013363548A1 (fr)
BR (1) BR112015012708A2 (fr)
CA (1) CA2892911C (fr)
CL (1) CL2015001639A1 (fr)
CY (1) CY1118254T1 (fr)
DK (1) DK2931748T3 (fr)
EA (1) EA201590918A1 (fr)
ES (1) ES2608381T3 (fr)
HR (1) HRP20161587T1 (fr)
HU (1) HUE032431T2 (fr)
IL (1) IL239242A0 (fr)
LT (1) LT2931748T (fr)
MA (1) MA38161A1 (fr)
ME (1) ME02515B (fr)
MX (1) MX2015007831A (fr)
PE (1) PE20151164A1 (fr)
PH (1) PH12015501360A1 (fr)
PL (1) PL2931748T3 (fr)
PT (1) PT2931748T (fr)
RS (1) RS55413B1 (fr)
SG (1) SG11201504695QA (fr)
SI (1) SI2931748T1 (fr)
TN (1) TN2015000277A1 (fr)
TW (1) TW201439118A (fr)
WO (1) WO2014099391A1 (fr)
ZA (1) ZA201504282B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR093620A1 (es) * 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
GB2550114A (en) * 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
EP3471759A1 (fr) * 2016-06-15 2019-04-24 Novartis AG Méthodes de traitement de maladie à l'aide d'inhibiteurs de la protéine morphogénétique osseuse 6 (bmp6)
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
WO2020251924A1 (fr) * 2019-06-12 2020-12-17 Regeneron Pharmaceuticals, Inc. Anticorps humains dirigés contre la protéine morphogénétique osseuse 6
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
US12215170B2 (en) 2020-04-07 2025-02-04 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
WO2021231798A1 (fr) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anticorps anti-hémojuvéline (hjv) pour le traitement de la myélofibrose
CN114075287B (zh) * 2020-08-18 2023-07-21 湖南远泰生物技术有限公司 人源化bcma抗体和bcma-car-t细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077006A1 (fr) 2001-03-23 2002-10-03 Human Genome Sciences, Inc. Polynucleotides, polypeptides et anticorps de proteines de la morphogenese osseuse
US7968091B2 (en) 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
JP6018753B2 (ja) * 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
US20110070242A1 (en) 2009-09-01 2011-03-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Iron Dysregulation
AR093620A1 (es) * 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6

Also Published As

Publication number Publication date
PH12015501360A1 (en) 2015-09-02
DK2931748T3 (da) 2017-01-02
MX2015007831A (es) 2015-08-20
CN104870473B (zh) 2018-05-29
ZA201504282B (en) 2017-11-29
CY1118254T1 (el) 2017-06-28
US20140309404A1 (en) 2014-10-16
SG11201504695QA (en) 2015-07-30
TN2015000277A1 (en) 2016-10-03
TW201439118A (zh) 2014-10-16
AP2015008600A0 (en) 2015-07-31
RS55413B1 (sr) 2017-04-28
CA2892911C (fr) 2017-02-28
EP2931748B1 (fr) 2016-10-05
EA201590918A1 (ru) 2015-10-30
HRP20161587T1 (hr) 2017-01-13
SI2931748T1 (sl) 2017-01-31
EP2931748A1 (fr) 2015-10-21
LT2931748T (lt) 2017-01-10
CL2015001639A1 (es) 2015-10-02
US8980582B2 (en) 2015-03-17
AR093620A1 (es) 2015-06-10
PE20151164A1 (es) 2015-08-19
PT2931748T (pt) 2016-11-02
US20140170161A1 (en) 2014-06-19
AU2013363548A1 (en) 2015-05-28
PL2931748T3 (pl) 2017-05-31
JP6033459B2 (ja) 2016-11-30
WO2014099391A1 (fr) 2014-06-26
ES2608381T3 (es) 2017-04-10
HUE032431T2 (en) 2017-09-28
BR112015012708A2 (pt) 2017-09-12
HK1209763A1 (en) 2016-04-08
CA2892911A1 (fr) 2014-06-26
ME02515B (fr) 2017-02-20
KR20150083918A (ko) 2015-07-20
CN104870473A (zh) 2015-08-26
JP2016501273A (ja) 2016-01-18
IL239242A0 (en) 2015-07-30
US8795665B2 (en) 2014-08-05

Similar Documents

Publication Publication Date Title
MA38161A1 (fr) Anticorps anti-bmp-6
MA40476B1 (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MA40913A (fr) Conjugués anticorps-médicament
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
MA34647B1 (fr) Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17
MA35433B1 (fr) Anticorps anti-pcsk9 et leurs utilisations
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
UA114891C2 (uk) ІЗОЛЬОВАНЕ АНТИТІЛО ЛЮДИНИ, ЯКЕ СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З АНГІОПОЕТИНПОДІБНИМ БІЛКОМ 3 ЛЮДИНИ (hАNGPTL3), ТА ЙОГО ЗАСТОСУВАННЯ
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
MA40041A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA40662B1 (fr) Anticorps contre tigit
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
MA34461B1 (fr) Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EA202091747A1 (ru) Составы антитела b7-h4
WO2018194496A3 (fr) Anticorps monoclonal à pd-l1
MA37670A1 (fr) Anticorps anti-transglutaminase 2
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.